BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21269258)

  • 1. Focal adhesion kinase as a therapeutic target of bortezomib.
    Ko BS; Chang TC; Liou JY
    Anticancer Agents Med Chem; 2010 Dec; 10(10):747-52. PubMed ID: 21269258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.
    Ko BS; Chang TC; Chen CH; Liu CC; Kuo CC; Hsu C; Shen YC; Shen TL; Golubovskaya VM; Chang CC; Shyue SK; Liou JY
    Life Sci; 2010 Jan; 86(5-6):199-206. PubMed ID: 20006625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of focal adhesion kinase by 14-3-3ε via NFκB activation in hepatocellular carcinoma.
    Ko BS; Jan YJ; Chang TC; Liang SM; Chen SC; Liu TA; Wu YM; Wang J; Liou JY
    Anticancer Agents Med Chem; 2013 May; 13(4):555-62. PubMed ID: 22934705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Proteasome inhibitor].
    Yamamura M; Hirai T; Yamaguchi Y
    Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG; Anderson KC
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
    Caravita T; de Fabritiis P; Palumbo A; Amadori S; Boccadoro M
    Nat Clin Pract Oncol; 2006 Jul; 3(7):374-87. PubMed ID: 16826218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal adhesion kinase: a potential target in cancer therapy.
    van Nimwegen MJ; van de Water B
    Biochem Pharmacol; 2007 Mar; 73(5):597-609. PubMed ID: 16997283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.
    Dick LR; Fleming PE
    Drug Discov Today; 2010 Mar; 15(5-6):243-9. PubMed ID: 20116451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological and clinical profile of Bortezomib (Velcade)].
    Fujii H; Kotobuki Y; Nomura S; Harada Y
    Nihon Yakurigaku Zasshi; 2007 Nov; 130(5):421-9. PubMed ID: 18000359
    [No Abstract]   [Full Text] [Related]  

  • 11. [Proteasome inhibitor bortezomib as an anticancer drug].
    Yasui H; Hideshima T
    Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
    [No Abstract]   [Full Text] [Related]  

  • 12. Proteasome: an emerging target for cancer therapy.
    Zavrski I; Jakob C; Schmid P; Krebbel H; Kaiser M; Fleissner C; Rosche M; Possinger K; Sezer O
    Anticancer Drugs; 2005 Jun; 16(5):475-81. PubMed ID: 15846112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential for proteasome inhibition in the treatment of cancer.
    Adams J
    Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib: proteasome inhibition as an effective anticancer therapy.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Annu Rev Med; 2006; 57():33-47. PubMed ID: 16409135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Coleman M
    Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
    Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
    Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitors in cancer therapy.
    Testa U
    Curr Drug Targets; 2009 Oct; 10(10):968-81. PubMed ID: 19548862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of the proteasome inhibitor Velcade (Bortezomib).
    Adams J; Kauffman M
    Cancer Invest; 2004; 22(2):304-11. PubMed ID: 15199612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.
    Montagut C; Rovira A; Mellado B; Gascon P; Ross JS; Albanell J
    Drugs Today (Barc); 2005 May; 41(5):299-315. PubMed ID: 16082428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.